Safety, tolerability, and pharmacokinetics of single‐ and multiple‐ascending doses of olamkicept: Results from randomized, placebo‐controlled, first‐in‐human phase I trials

Documenti analoghi

• A phase I, randomized, placebo‐controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults
  di: Xiaomeng Mao, et al.
  Pubblicazione: (2024)
• Randomized, double‐blind, phase 1a single‐ascending dose and food effect studies assessing safety and pharmacokinetics of EC5026 in healthy volunteers
  di: William K. Schmidt, et al.
  Pubblicazione: (2024)
• Spatial and single‐cell RNA sequencing reveals the immune microenvironment of human ascending thoracic aortic aneurysms
  di: Ke Zhen, et al.
  Pubblicazione: (2026)
• Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral allosteric TYK2 inhibitor ESK‐001 using a randomized, double‐blind, placebo‐controlled study design
  di: Sibel Ucpinar, et al.
  Pubblicazione: (2024)
• Pharmacokinetics, pharmacodynamics, and safety of izuforant, an H4R inhibitor, in healthy subjects: A phase I single and multiple ascending dose study
  di: Byung Hak Jin, et al.
  Pubblicazione: (2024)